Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Crossbow Therapeutics, OpenAI, and 370+ companies. 5-min read every Tuesday.
Biotech company developing precision antibody therapies for cancer treatment
| Industry | Biotech / Oncology |
| Stage | series_b |
| IPO Status | Pre-IPO |
| Total Funding | $180M |
| Headquarters | Cambridge, MA |
OpenAI is valued at $852B — the world's most valuable AI company, backed by $27B in funding. Track IPO readiness score, funding rounds, and timeline.
| Industry | Artificial Intelligence |
| Stage | Pre-IPO |
| IPO Status | Pre-IPO |
| Valuation | $852B |
| Total Funding | $55.4B |
| Headquarters | San Francisco, CA |
Crossbow Therapeutics's valuation is not publicly disclosed. OpenAI is valued at $852B. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Crossbow Therapeutics has raised $180M. OpenAI has raised $55.4B.
Crossbow Therapeutics is currently pre-IPO. OpenAI is currently pre-IPO. Track both on TechStackIPO for S-1 filings and IPO announcements.
Crossbow Therapeutics operates in Biotech / Oncology, while OpenAI operates in Artificial Intelligence.
Crossbow Therapeutics is a Biotech / Oncology company with $180M raised. OpenAI is a Artificial Intelligence company valued at $852B with $55.4B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Crossbow Therapeutics and OpenAI through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.